Cover Image

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Yue Yin, Minghan Zhang, Qiuyu Cao, Lin Lin, Jieli Lu, Yufang Bi, Yuhong Chen
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Journal of Diabetes
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Gastrointestinal Safety of Orforglipron, a GLP ‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
by: Ahmed W. Hageen, et al.
Published: (2026)

An Update on GLP‐1 Receptor Agonists
by: Zachary Bloomgarden
Published: (2025)

RETRACTION : Effects of GLP ‐1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis Based on Randomized Controlled Trials
Published: (2026)

Impact of GLP ‐1 Receptor Agonist Discontinuation on Liver‐Related Parameters: A Systematic Review and Meta‐Analysis
by: Matheus Souza, et al.
Published: (2026)

Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis
by: Ravi Kumar Pandey, et al.
Published: (2025)

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
by: Tahmid Hussain, et al.
Published: (2026)

GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
by: Cynthia F. X. C. A. Silva, et al.
Published: (2026)

Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without CKD : A Post Hoc Analysis of SPRINT and ACCORD ‐ BP Trials
by: Xiaoli Xu, et al.
Published: (2025)

The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis
by: Shih‐Ming Chuang, et al.
Published: (2026)

Searching the Crystal Ball for Tailored GLP‐1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity
by: Asia Saturnino, et al.
Published: (2024)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
by: Roberta Scairati, et al.
Published: (2026)

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials
by: Ayah Abulehia, et al.
Published: (2026)

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
by: Jirawan Vienghirun, et al.
Published: (2026)

Cardiometabolic Profiles and Treatment Trajectories of GLP ‐1 Receptor Agonist Users With Obstructive Sleep Apnea: Real‐World Evidence From a Large Private Healthcare Cohort in Poland
by: Klaudia Nowak, et al.
Published: (2026)

GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation
by: Haisheng Wu, et al.
Published: (2026)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
by: Inyoung Hwang, et al.
Published: (2026)

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
by: A. G. Barajas, et al.
Published: (2025)

Weight Loss Outcomes Between GLP ‐1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta‐Analysis and Meta‐Regression
by: Muhammad Tahir, et al.
Published: (2026)

Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
by: Rayanne Santos de Paulo, et al.
Published: (2026)

Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP ‐1 Receptor Agonists: A Machine Learning–Based Analysis of a Large Real World Cohort
by: Pierpaolo Falcetta, et al.
Published: (2026)

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
by: Yazan Alhamdan, et al.
Published: (2026)

Reply: Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
by: Zhiyuan Cheng, et al.
Published: (2026)

Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
by: Ahmed Y. Azzam, et al.
Published: (2025)

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta‐Analysis of Clinical Trials
by: Celina R. Andonie, et al.
Published: (2025)

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
by: Lasin Ozbek, et al.
Published: (2026)

Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis
by: Yucheng Yang, et al.
Published: (2025)

Comparison of Benefits and Risks of Metabolic Surgery for Long‐Term (5 Years) Weight Loss and Diabetes Remission in Overweight/Obese Patients With Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomized Trials
by: Xiaoyu Zang, et al.
Published: (2025)

Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study
by: Daniel Yuan, et al.
Published: (2025)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
by: Abdur Rafay Bilal, et al.
Published: (2026)

One in Five Atherosclerotic Cardiovascular Disease Events in Individuals With Diabetes Attributed to Elevated Remnant Cholesterol
by: Benjamin N. Wadström, et al.
Published: (2024)

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
by: Saixian Shi, et al.
Published: (2025)

Analysis of HMGCS2 Expression and TG Lipidomics in the Perirenal Adipose Tissue of Obese Diabetic Nephropathy Mice
by: Yuhong Huang, et al.
Published: (2025)

Beyond GLP ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
by: Mikhail Khachaturov, et al.
Published: (2026)

Usefulness of Once‐Weekly GLP‐1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
by: Tomohiko Kimura, et al.
Published: (2024)

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study
by: Takeshi Miyatsuka, et al.
Published: (2026)

Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
by: Fei Lu
Published: (2026)

Association of Glucagon‐Like Peptide‐1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
by: Shumeng Han, et al.
Published: (2026)

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024)

Methodological Concerns Regarding BMI Imbalance and Competing Risks in a Head‐to‐Head Comparison of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists for Incident Dementia
by: Shio‐Shin Jean, et al.
Published: (2026)

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis
by: A. B. M. Kamrul‐Hasan, et al.
Published: (2026)